- Home
- SIGI vs GH Comparison
SIGI vs GH Comparison
Compare SIGI & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGI
- GH
- Stock Information
- Founded
- SIGI 1926
- GH 2011
- Country
- SIGI United States
- GH United States
- Employees
- SIGI N/A
- GH N/A
- Industry
- SIGI Property-Casualty Insurers
- GH Medical Specialities
- Sector
- SIGI Finance
- GH Health Care
- Exchange
- SIGI Nasdaq
- GH Nasdaq
- Market Cap
- SIGI 5.2B
- GH 4.9B
- IPO Year
- SIGI N/A
- GH 2018
- Fundamental
- Price
- SIGI $85.12
- GH $49.14
- Analyst Decision
- SIGI Hold
- GH Strong Buy
- Analyst Count
- SIGI 8
- GH 20
- Target Price
- SIGI $94.00
- GH $54.35
- AVG Volume (30 Days)
- SIGI 347.8K
- GH 2.2M
- Earning Date
- SIGI 07-17-2025
- GH 08-06-2025
- Dividend Yield
- SIGI 1.77%
- GH N/A
- EPS Growth
- SIGI N/A
- GH N/A
- EPS
- SIGI 3.68
- GH N/A
- Revenue
- SIGI $4,981,891,000.00
- GH $773,996,000.00
- Revenue This Year
- SIGI $6.05
- GH $23.14
- Revenue Next Year
- SIGI $7.43
- GH $21.42
- P/E Ratio
- SIGI $23.15
- GH N/A
- Revenue Growth
- SIGI 13.30
- GH 28.20
- 52 Week Low
- SIGI $78.13
- GH $20.14
- 52 Week High
- SIGI $103.56
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- SIGI 41.08
- GH 62.17
- Support Level
- SIGI $83.76
- GH $48.00
- Resistance Level
- SIGI $86.05
- GH $51.71
- Average True Range (ATR)
- SIGI 1.97
- GH 2.67
- MACD
- SIGI -0.17
- GH 0.39
- Stochastic Oscillator
- SIGI 21.94
- GH 78.60
About SIGI Selective Insurance Group Inc.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, Investments. Majority of revenue is gained from Standard Personal Lines. Currently company has it's revenues from States of USA and Columbia.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.